CADL today
$9.22-$0.13 (-1.39%)close Nov 11, 2026Trend
DailyUptrend (starting)
4 hourExpanding
1 hourSymmetric Triangle
15 minExpanding
5 minStrong Bearish
Daily trend turns down below $3.79
Key levels
Resistance$11.36
Resistance$10.18
Support$8.88
Support$8.01
Latest news & SEC filings
NewsCandel Therapeutics Shares Study Findings at SITC Annual Meeting
NewsCandel Therapeutics gives equity awards to newly hired top legal officer
ProductCandel Therapeutics wins late-breaking abstract spot at SITC 2026 meeting
All CADL news →About Candel Therapeutics
Candel Therapeutics develops virus-based cancer immunotherapies that are meant to trigger a body-wide immune attack on tumors. Its main candidates are aglatimagene, an adenovirus therapy paired with valacyclovir, and linoserpaturev, built from herpes simplex virus. These are studied in prostate, lung, pancreatic, and brain cancers. The company holds rights to its programs across major markets worldwide.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
Candel Therapeutics, Inc. (CADL)
What Is the Price Target for CADL?
SEPT Low Target
$18.00
SEPT Mid Target
$22.00
SEPT High Target
$25.00
Analyst Consensus
$22.00
Is CADL a Buy or Sell Right Now?
Thesis
- •Revenue growing 0.0% YoY with UNKNOWN trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CADL.
Start Free Trial →Is CADL Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$17.58
4
Moat Score
NONE
2/9
Piotroski Score
0.8
Altman Z-Score
What Is Smart Money Doing with CADL?
Insider Signal
NEUTRAL
1 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Tak Paul Peter | director officer | Sale | 59,379 | $621K | Sep 11, 2026 |
| Tak Paul Peter | director officer | Buy | 125,000 | $194K | Sep 10, 2026 |
| Tak Paul Peter | director officer | Sale | 220,866 | $2.5M | Sep 10, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CADL Growth Story
Revenue YoY
0.0%
3yr Revenue CAGR
N/A%
EPS Growth YoY
58.62%
FCF Growth YoY
-43.9%
Revenue Trend
UNKNOWN
Dark Pool Trades for CADL
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CADL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:06:38 | $9.30 | 12,537 | $$117K | SELL |
| 21:00:29 | $9.22 | 5,719 | $$53K | SELL |
| 20:59:47 | $9.21 | 7,200 | $$66K | SELL |
| 20:55:11 | $9.21 | 5,000 | $$46K | SELL |
| 20:54:04 | $9.24 | 1,500 | $$14K | MIDPOINT |
5 dark pool trades shown · $$296K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About CADL
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for CADL. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $CADL (Candel Therapeutics, Inc.) Price: $9.68 | Zone: $9.26 to $10.50 Conviction: HIGH | Analyst upside: +114.2% Near resistance (34% of range) — breakout watch. Strong positive news ...
Join 3,500+ traders discussing CADL in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Candel Therapeutics, Inc. (CADL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CADL — frequently asked questions
What is CADL stock price today?
Candel Therapeutics, Inc. (CADL) is at $9.22, down 1.39% (-$0.13) at the Nov 11, 2026 close.
Why is CADL stock moving today?
Latest CADL news — Nov 7, 2026: Candel Therapeutics Shares Study Findings at SITC Annual Meeting · Nov 6, 2026: Candel Therapeutics gives equity awards to newly hired top legal officer
What is the CADL price target?
The average analyst price target for CADL is $22.00, ranging from $18 to $25, based on 5 analysts. Latest: Jefferies initiates on Oct 22, 2026.
What do analysts rate CADL?
Analyst ratings for CADL: 2 Buy, 7 Hold, 0 Sell — consensus Hold.
Did CADL beat earnings?
CADL last reported on Aug 13, 2026: EPS -$0.52 vs -$0.24 expected — a miss of 118.6%.
Does CADL pay a dividend?
CADL does not currently pay a dividend.
What are CADL support and resistance levels?
Support: $8.88, $8.01, $7.37. Resistance: $10.18, $11.36, $12.01.
What are insiders doing with CADL?
Insider activity: NEUTRAL, 1 buys and 2 sells in the last 90 days.
What is the latest news on CADL?
Nov 7, 2026: Candel Therapeutics Shares Study Findings at SITC Annual Meeting · Nov 6, 2026: Candel Therapeutics gives equity awards to newly hired top legal officer · Oct 29, 2026: Candel Therapeutics wins late-breaking abstract spot at SITC 2026 meeting